Food allergy is a major health problem of growing concern affecting more than an estimated 30 million people in Europe, United States, and Canada. Living with food allergy may have a great impact on the quality of life of a patient, due to a fear of severe reactions or even anaphylaxis from accidental ingestion of the offending foods. Currently, the treatment options are very limited, and thus there is a significant unmet medical need for safe, efficacious and convenient treatment options.
The project ALLEVIATE2 will use a new strategy in an effort to complete the preclinical development of sublingual immunotherapy drug candidates for the treatment of peanut allergy. If successful, the project will subsequently apply the same therapeutic approach to developing treatments for multiple tree nut allergies.
Goals are to improve safety, efficacy and convenience
"The project’s aim is to pave the way for a radical improvement in the treatment options for food allergies by developing treatments with an improved safety, efficacy and convenience profile versus current options. The products we want to develop could have a great impact in improving quality of life for people with food allergies," says project manager, Senior Researcher and Head of Research Group, Katrine Lindholm Bøgh, DTU National Food Institute.
The US FDA approved the first ever drug for food allergy immunotherapy in January 2020, thereby creating new opportunities within the emerging food allergy immunotherapy market. The ALLEVIATE2 project aims to generate innovative breakthroughs that will place Denmark and its collaborators at the forefront of innovation within food allergy immunotherapy. Success of this project could lead to attracting more students, researchers, entrepreneurs and investors to Denmark from around the world, stimulating new job opportunities in both academia and industry.
Collaboration.
